Clinical Consult

Eytan Stein, MD, discusses the management of chemotherapy-ineligible AML, as well as the effect of venetoclax in combination with HMA as a new therapy.

Best practices for the use of gene profiling assays to guide treatment decisions for patients with early-stage HR-positive breast cancer.

Sagar Lonial, MD, FACP, explains the various ways to target and treat relapsed/refractory multiple myeloma, specifically focusing on BCMA and belantamab mafoditin as therapeutic agents.

Dr. Rebecca Previs from the Duke Cancer Center reviews frontline therapy options for patients with advanced ovarian cancer.

Anthony Lucci, MD, provides insight on the management of early-stage breast cancer and evolving therapeutic approaches for patients due to the COVID-19 pandemic.

Thomas Herzog, MD, provides insight on key clinical trials and the use of PARP inhibition in frontline maintenance therapy for ovarian cancer.

BCMA targeting agents such as the antibody-drug conjugate belantamab mafodotin show promise for heavily pretreated patients with relapsed/refractory multiple myeloma

The rationale for using BCMA-targeted novel approaches such as antibody-drug conjugates, bispecific antibodies, and CAR T-cell therapies as treatment for patients with heavily pretreated relapsed/refractory multiple myeloma.

ONCOLOGY® recently sat down with Jane L. Meisel, MD, of Emory University School of Medicine in Atlanta, Georgia, to discuss how these data from the TAILORx trial validate and inform the current and future care of patients with breast cancer.